Subcutaneous daratumumab: combining efficacy, safety & amp; convenience
IV administration of daratumumab has several issues, including a long infusion time (~7 h) and the likelihood of infusion-related toxicities. In this video, recorded at the 2018 American Society of On...
Author: VJHemOnc
Added: 07/27/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Cancer & Oncology | Toxicology